Home  |  Contact

Cellosaurus CWR-R1-EnzR (CVCL_RA55)

[Text version]

Cell line name CWR-R1-EnzR
Accession CVCL_RA55
Resource Identification Initiative To cite this cell line use: CWR-R1-EnzR (RRID:CVCL_RA55)
Comments Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
Omics: Transcriptome analysis.
Derived from sampling site: Prostate.
Sequence variations
  • Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line).
Disease Prostate carcinoma (NCIt: C4863)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_4833 (CWR-R1)
Sex of cell Male
Age at sampling Adult
Category Cancer cell line

PubMed=27036029; DOI=10.18632/oncotarget.8456
Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H., Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z., Vander Griend D.J.
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Oncotarget 7:26259-26274(2016)

Encyclopedic resources Wikidata; Q54817050
Gene expression databases GEO; GSM2069494
GEO; GSM2069495
GEO; GSM2069496
GEO; GSM2069497
Entry history
Entry creation05-Mar-2018
Last entry update20-May-2021
Version number7